NASDAQ:FULC - Fulcrum Therapeutics News Headlines

$9.45
+0.32 (+3.50 %)
(As of 09/18/2019 03:19 AM ET)
Add
Compare
Today's Range
$8.91
Now: $9.45▼
$9.98
50-Day Range
$8.77
MA: $11.19▼
$14.60
52-Week Range
$8.19
Now: $9.45▼
$15.94
Volume21,100 shs
Average Volume70,698 shs
Market Capitalization$220.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Fulcrum Therapeutics (NASDAQ FULC) News Headlines

Source:
DateHeadline
Fulcrum Therapeutics (NASDAQ:FULC) Director Rock Ventures Iii L.P. Third Acquires 61,280 SharesFulcrum Therapeutics (NASDAQ:FULC) Director Rock Ventures Iii L.P. Third Acquires 61,280 Shares
www.americanbankingnews.com - September 9 at 4:41 PM
Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs TeamFulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team
finance.yahoo.com - September 4 at 9:32 AM
Fulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare ConferenceFulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
finance.yahoo.com - September 3 at 8:23 PM
Svb Leerink Research Analysts Decrease Earnings Estimates for Fulcrum Therapeutics (NASDAQ:FULC)Svb Leerink Research Analysts Decrease Earnings Estimates for Fulcrum Therapeutics (NASDAQ:FULC)
www.americanbankingnews.com - August 30 at 5:56 AM
Fulcrum Therapeutics to Post Q1 2020 Earnings of ($0.43) Per Share, Svb Leerink Forecasts (NASDAQ:FULC)Fulcrum Therapeutics to Post Q1 2020 Earnings of ($0.43) Per Share, Svb Leerink Forecasts (NASDAQ:FULC)
www.americanbankingnews.com - August 29 at 7:59 AM
Fulcrum Therapeutics (NASDAQ:FULC) Announces Quarterly Earnings ResultsFulcrum Therapeutics (NASDAQ:FULC) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 27 at 10:32 AM
Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business HighlightsFulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - August 26 at 3:22 PM
Fulcrum launches mid-stage study of losmapimod in FSHDFulcrum launches mid-stage study of losmapimod in FSHD
seekingalpha.com - August 19 at 3:18 PM
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHDFulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
finance.yahoo.com - August 19 at 3:18 PM
Stocks To Watch: Walmart And Alibaba Step To The PlateStocks To Watch: Walmart And Alibaba Step To The Plate
seekingalpha.com - August 11 at 7:14 AM
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases ConferenceFulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
finance.yahoo.com - August 1 at 8:17 PM
Fulcrum Therapeutics IPO: What You Need To KnowFulcrum Therapeutics IPO: What You Need To Know
finance.yahoo.com - July 24 at 9:29 PM
IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of ChinaIPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China
finance.yahoo.com - July 24 at 9:29 PM
Fulcrum Therapeutics Announces Pricing of Initial Public OfferingFulcrum Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - July 24 at 9:29 PM
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Featured Article: Outstanding Shares and The Effect on Share Price
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel